Last reviewed · How we verify
ANX009
At a glance
| Generic name | ANX009 |
|---|---|
| Also known as | Recombinant humanized immunoglobulin G1 (IgG1) Fab, 009 |
| Sponsor | Annexon, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of ANX009 in Adult Participants With Lupus Nephritis (PHASE1)
- A Single and Multiple Ascending Dose Study of ANX009 in Normal Healthy Volunteers (NHV) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ANX009 CI brief — competitive landscape report
- ANX009 updates RSS · CI watch RSS
- Annexon, Inc. portfolio CI